Interleukin-6 released by oral lichen planus myofibroblasts promotes angiogenesis

XIAO-HENG XU1*, YANG LIU1*, LU FENG1, YIN-SHEN YANG1, SHU-GUANG LIU2, WEI GUO3, HUI-XI ZHOU2, ZHI-QIANG LI2, LIN ZHANG1 and WEN-XIA MENG1

Departments of 1Oral Medicine, 2Oral Surgery and 3Oral Pathology, Stomatological Hospital, Southern Medical University, Guangzhou, Guangdong 510280, P.R. China

Received February 21, 2020; Accepted August 13, 2020

DOI: 10.3892/etm.2021.9722

Abstract. Oral lichen planus (OLP), defined as a potential for malignant transformation, is a chronic inflammatory disease in which abnormal angiogenesis serves a role in the malignant changes of the disease. OLP-associated fibroblasts (OLP-MFs), derived from the stroma of OLP tissues, are characterized by the presence of myofibroblasts and contribute to the secretion of pro-inflammatory cytokines, which may be involved in the molecular pathogenesis of OLP. However, the associated mechanisms of angiogenesis in OLP remain unknown. The present study aimed to verify the expression of intercellular adhesion molecular 1, vascular cell adhesion molecule 1, VEGF and CD34 in OLP, and to investigate whether IL-6 secreted by OLP-MFs promoted OLP angiogenesis and the effect of its corresponding antibody inhibition. The results of the experiments demonstrated that inflammation was present and OLP upregulated the secretion of IL-6 by OLP stromal fibroblasts, thereby enhancing OLP angiogenesis. Anti-IL-6 receptor antibody inhibited OLP-stroma IL-6 signaling and suppressed OLP angiogenesis. The antibody inhibited the inflammatory response by inhibiting the secretion of inflammatory factors, including IL-6, to suppress angiogenesis and reduce disease progression, thus indicating that this could be a potential target to develop a treatment for OLP.

Introduction

Oral lichen planus (OLP), a chronic inflammatory disease, has the potential for malignant transformation, with a high malignancy risk of erosive OLP (EOLP) (1). Previous studies demonstrated that angiogenesis served a major role in chronic inflammatory diseases, including Crohn’s Disease, rheumatoid arthritis and atherosclerosis (1-3). Although the etiology of OLP remains unknown (4), the role of angiogenesis in the development of OLP is of considerable concern. A previous study has stated that angiogenesis is significantly increased in OLP compared with normal oral mucosa (5). To the best of our knowledge, a previous clinical study was the first to report that anti-angiogenic therapy exerted a positive effect on the management of OLP (6). Therefore, an in-depth understanding of angiogenesis is needed to provide an insight into the pathogenesis and progression of OLP, which may provide insight for clinicians for the management of OLP.

Previous studies have demonstrated that activated fibroblasts, also termed myofibroblasts (MFs), are involved in the development of neoplasms and certain inflammatory processes, such as cardiac fibrosis and cirrhosis (7-9). Portal myofibroblasts promote vascular remodeling underlying cirrhosis formation by releasing microparticles (10). A previous study suggested that OLP-associated fibroblasts acquired the characteristics of myofibroblasts (termed OLP/MFs) (11). Immunophenotypically, myofibroblasts are characterized by the expression of abundant pericellular matrix proteins, including vimentin, α-smooth muscle actin (α-SMA) and fibroblast activation protein (FAP) (11). It was hypothesized that fibroblasts in OLP connective tissues affected by the inflammatory environment may be involved in the molecular pathogenesis underlying OLP.

In recent years, previous studies have reported that IL-6 produced by carcinoma-associated fibroblasts (CAFs) is critical for tumor angiogenesis (12,13). However, the role of OLP/MFs in angiogenesis and whether IL-6 promotes angiogenesis in OLP and the underlying mechanisms have not yet been reported. The present study investigated the expression of various vascular markers in OLP. Additionally, OLP/MFs were isolated and cultured in vitro and, to the best of our knowledge, the present study was the first to report the biological characteristics of OLP/MFs. This strategy aimed to elucidate whether the putative effects of IL-6 released by OLP/MFs were critical for OLP angiogenesis.

Materials and methods

Tissue collection. Human OLP specimens from patients diagnosed with OLP without epithelial dysplasia and normal
oral squamous epithelium tissues from patients undergoing plastic surgery were collected from the Stomatological Hospital of Southern Medical University (Guangzhou, China) from January 2018 to January 2019. Patients were excluded if they had severe systemic diseases, received drug treatment in the past 4 weeks, or suffered other oral mucosal diseases. The OLP tissues were divided into EOLP and NEOLP groups. The protocol was reviewed by the Institutional Ethics Committee of this hospital [approval no. (2019)26]. Each patient signed an informed consent form. A total of 15 normal epithelium tissues and 25 OLP samples were utilized for immunohistochemistry (IHC) and the clinical features of the participants are presented in Table I. All surgically-resected tissues were collected for histopathological confirmation.

**IHC analysis and microvessel density (MVD) analysis.** The tissue samples were fixed in 4% formalin at room temperature for 24 h. Sections were deparaffinized in xylene, rehydrated in an alcohol gradient and embed with epoxy resin. The 3 μm thick mucosal sections were processed for histology. The antigen retrieval was performed using the wet autoclaving method in the presence of citrate buffer pH 6.0. The sections were blocked with 1% BSA/PBS at 37°C for 30 min. Immunostaining for vascular cell adhesion molecule 1 (VCAM-1, also known as CD106; 1:60; cat. no. ab134047; Abcam), intracellular adhesion molecule 1 (ICAM-1, also known as CD54; 1:100; cat. no. ab222736; Abcam), VEGF (1:100; cat. no. ab46154; Abcam) and CD34 (1:500; cat. no. ab81289; Abcam) was performed using mouse monoclonal antibodies with the DakoCytomation EnVision® system (Dako; Agilent Technologies, Inc.), according to the manufacturer's protocols. The tissue was incubated with the primary antibodies overnight at 4°C. Subsequently, the sections were incubated with anti-rabbit-HRP (1:50; cat. no. PV-9000; ZSGB-BIO.) or anti-mouse-HRP (1:50; cat. no. PV-9000; ZSGB-BIO.) at room temperature for 30 min. The stained tissue samples were incubated with 10% normal goat serum at room temperature for 30 min. The DAB REAL EnVision Detection System (cat. no. K5007; DAKO; Agilent Technologies, Inc.) was used for color development. Slides were counterstained with modified Harris hematoxylin (Thermo Fisher Scientific, Inc). Excess dye solution was then washed away and the slides were mounted using neutral gum mounting film. Images were captured using an inverted light microscope (magnification, x200 and x400; BX51; Olympus Corporation). Immunoreactivity was scored as: i) 0, absent; ii) 1, ≤25% positive cells; iii) 2, 26-75% positive cells; or iv) 3, >75% positive cells. OLP were assessed as: i) 0, absent; ii) 1, ≤25% positive cells; iii) 2, 26-75% positive cells; or iv) 3, >75% positive cells. OLP were assessed using a Cell Counting Kit-8 (CCK-8; Dojindo Molecular Technologies, Inc.) at 24, 48 and 72 h, according to the manufacturer's protocol. The cells were rinsed with PBS and fixed overnight in 3% glutaraldehyde at 4°C. Subsequently, the samples were dehydrated using the following ethanol gradient: 30, 50, 70, 95 and 100%. The samples were then dehydrated with xylene, air-dried at room temperature and embed with epoxy resin. The specimens were coated with gold. The ultrastructure of OLP-MFs and NFs was compared using a transmission electron microscope (magnification, x1.2k) and scanning electron microscopy (magnification, x700), respectively. The images were processed using Adobe Photoshop CS6 (Version 13.0.1; Adobe Systems, Inc.).

**Wound healing assays.** Wound healing assays were used to detect the migration of OLP-MFs and NFs at different time points (0, 24 and 48 h). Cells were grown in 24-well plates (at a seeding density of 5.0x10^5 cells/well) in medium (DMEM, high glucose; Gibco; Thermo Fisher Scientific, Inc.) supplemented with 10% FBS. After the cells grow into a monolayer, the medium was discarded and a sterile pipette tip was used to scratch the center of the monolayer at the bottom of the 24-well plate, perpendicular to the marking line. The samples were rinsed with PBS solution 3 times and 1% serum media, as aforementioned, was added. Images were captured using an inverted light microscope (TE2000; Nikon Corporation) at the aforementioned time points. The acquired images were used to calculate the migration rate of cells using the image analyzing software, ImageJ (version 1.46r; National Institutes of Health). The % closure (% of the surface area of the migrated cells into the defined wound area) was used to indirectly measure the cells migration rate. Closure (%)=(migrated cell surface area/total surface area) x100. A total of 3 replicates of the OLP-MFs and 3 NFs cell lines were selected for reverse transcription-quantitative PCR (RT-qPCR) and western blot analysis.

**RT-qPCR.** Cells were grown in 24-well plates (at a seeding density of 1.0x10^5 cells/well) were treated with 100 ng/ml Toll-like receptor ligand pg-lipopolysaccharide
levels in each cultured OLP-MFs and NFs were evaluated using ELISA. GAPDH was used as the loading control. Chemicon International; Thermo Fisher Scientific, Inc.) were used, with GAPDH being used as the loading control. Smooth muscle Actin antibody (1:2,000; cat. no. ab5694; Abcam) and GAPDH (clone 6C5; 1:5,000; cat. no. MAB374-AF647; Chemicon International; Thermo Fisher Scientific, Inc.) were used, with GAPDH being used as the loading control.

All procedures were performed using the manufacturer's protocols. RT-qPCR was performed using the GoScript™ Reverse Transcription System (A5001; Promega Corporation) and GoTaq® qPCR Master Mix (Promega Corporation). The following thermocycling conditions were used: Initial denaturation at 95°C for 30 sec; followed by 40 cycles of 95°C for 5 sec and 60°C for 30 sec. The primers used to amplify α-SMA, IL-6, VEGF, VCAM-1 and ICAM-1 were listed in Table II. β-actin was used as the internal control. Experiments were performed in triplicate. The 2ΔΔCq method was used for quantification (15).

**Protein preparation and Simple Western analysis.** A total of 3 OLP-MFs and 3 NFs were selected for Simple Western analysis. Total protein expression of 3 OLP-MFs and 3 NFs primary cell lines. Total RNA from each sample was isolated using TRIzol® Universal reagent (Tiangen Biotech Co., Ltd.), according to the manufacturer's protocol. RT-qPCR was performed using the GoScript™ Reverse Transcription system (A5001; Promega Corporation) and GoTaq® qPCR Master Mix (Promega Corporation). The following thermocycling conditions were used: Initial denaturation at 95°C for 30 sec; followed by 40 cycles of 95°C for 5 sec and 60°C for 30 sec. The primers used to amplify α-SMA, IL-6, VEGF, VCAM-1 and ICAM-1 are listed in Table II. β-actin was used as the internal control. Experiments were performed in triplicate. The 2^ΔΔCq method was used for quantification (15).

**Table I. Clinical features of patients.**

| Patient group | Number | Age, years (mean ± SD) | Sex | Female | Male |
|---------------|--------|------------------------|-----|--------|------|
| OLP           | 25     | 46.50±5.54             |     | 16     | 9    |
| EOLP          | 14     | 46.50±3.54             |     | 10     | 4    |
| NEOLP         | 11     | 46.82±2.71             |     | 6      | 5    |
| Normal        | 15     | 43.53±3.44             |     | 8      | 7    |
| Total         | 40     | 45.48±12.05            |     | 24     | 16   |
| F-value       | 0.303  |                       |     | 0.560  |      |
| P-value        | 0.741  |                       |     | 0.576  |      |

OLP, oral lichen planus; EOLP, erosive OLP; NEOLP, non-erosive OLP. ns, P>0.05 Normal group vs. OLP group.

| Gene | Primer sequences (5'-3') |
|------|--------------------------|
| α-SMA | F: GTGTGTTGCCCTGAAGGACAT  
R: GCTGGGACATTGAAAGTCTCA |
| IL-6  | F: AACTCTGATTCAATGAGGAGACTT  
R: TCTGGTGGTTCCTCACACTCTC |
| VEGF  | F: GAGGCGAGAATCTACGGAAG  
R: TGATCTCGATCTACAGGGTACT |
| VCAM-1 | F: CATAAAGAAACTGGAAGGAGGAATC  
R: AGGGGTACACGCTAGGAAC |
| ICAM-1 | F: ATGCCCCAGACATGTTGTC  
R: GGGTGCTCTATGCGAAACAA |
| β-actin | F: CCTGGGACCCAGCACAAT  
R: GCTGGTACACATCTGCGGAA |

F, forward; R, reverse; α-SMA, α-smooth muscle actin; IL-6, interleukin 6; VEGF, vascular endothelial growth factor; VCAM-1, vascular cell adhesion molecule 1; ICAM-1, intercellular adhesion molecule 1.

Effect of IL-6 on angiogenesis-associated cytokine expression. Cells were treated with 1 ng/ml IL-6 (PeproTech, Inc.), 40 mg/ml soluble Interleukin-6 receptor (sIL-6R; Prospec-Tany TechnoGene, Ltd.) and 10 µg/ml tocilizumab (MRA; anti-human IL-6 receptor antibody; Selleck Chemicals) for 24 h (RT-qPCR) or 48 h (ELISA) at 37°C. VEGF, VCAM-1 and ICAM-1 mRNA expression levels were measured using RT-qPCR, as aforementioned. VEGF, VCAM-1 and ICAM-1 expression levels in cell culture supernatants were collected and measured using ELISA, as aforementioned.

**Cell migration.** NFs or OLP-MFs cell lines were seeded (seeding density, 1x10^6 cells/ml) into 6-well plates at a density of 4x10^6 cells/ml. Following overnight incubation at 37°C, cell lines were exposed to the conditions described in the following section and incubated with 10% FBS in DMEM. After 12, 24, 36 or 48 h, culture supernatants were collected, centrifuged at 1,000 x g at room temperature for 20 min to pellet any detached cells and measured using IL-6 ELISA Kit (cat. no. CSB-E04638h; Cusabio Technology LLC), VEGF (cat. no. DVE00; R&D Systems, Inc.), VCAM-1 (cat. no. DCV00; R&D Systems, Inc.) and ICAM-1 (cat. no. DCIM00; R&D Systems, Inc.) ELISA kits, according to the manufacturer's protocols.
under a light microscope (x100) and images were captured using a digital camera.

**Tube formation assay.** Human umbilical vein endothelial cells (HUVECs) were purchased from Procell Life Science & Technology Co., Ltd. A 96-well plate pre-coated with Matrigel was incubated at 37°C for 2 h. Following this, 2x10^4 HUVECs/well suspended in 100 µl conditioned medium were added with IL-6/sIL-6R and MRA by groups, and the groups were as follow: NFs/OLP-MFs + HUVECs, NFs/OLP-MFs + HUVECs + IL-6/sIL-6R, NFs/OLP-MFs + HUVECs + IL-6/sIL-6R + MRA. Following incubation at 37°C for 24 h, three fields were chosen at random, the number of capillary-like tubes were counted, and the number of branch points, number of branches and tube length were measured. Images were captured using an inverted microscope (x100) (TE2000; Nikon Corporation).

**Statistical analysis.** Data were analyzed using SPSS software (version 22.0; IBM Corp.). Student’s t-test and one-way ANOVAs were used to evaluate differences between sample groups when appropriate and Fisher’s least significant difference (LSD) test was used as the post hoc test. Data are presented as the mean ± SEM. P<0.05 was considered to indicate a statistically significant difference.

**Results**

**VCAM-1, ICAM-1, VEGF and CD34 expression in OLP.** To verify the expression of VCAM-1, ICAM-1, VEGF and CD34 in clinical samples and fully assess their association with the severity of OLP, 15 oral normal squamous epithelium tissues and 25 OLP tissues were examined. The results of IHC demonstrated that the expression levels of VCAM-1, ICAM-1, VEGF and CD34 were nearly undetectable in normal stromal cells (Fig. 1). Notably, low cytoplasmic expression of ICAM-1 and moderate expression of VCAM-1, VEGF and CD34 was detected in the normal tissues. Conversely, moderate-to-intense homogeneous cytoplasmic expression was observed in the OLP tissues and the positive staining in EOLP was significantly higher compared with non-erosive OLP (NEOLP), as shown in Fig. 1. Based on the number of positive cells, the expression of angiogenesis factors in OLP tissues was significantly higher compared with normal tissues. The results of the immunoreactivity assay of ICAM-1, VCAM-1 and VEGF in normal and OLP tissues is presented in Table III. MVD were observed...
in the inflammatory infiltrating area and surrounding areas (Fig. 1). The statistical results are presented in Table IV. In the present study, the mean MVD in OLP tissues (NEOLP and EOLP) was significantly higher compared with normal tissues (P<0.001). Additionally, the mean MVD of the EOLP group was obviously higher than that in the NEOLP group (P<0.001).

Charateristics of fibroblasts isolated from normal and OLP specimens. A total of 8 primary human OLP/MFs lines and 6 primary oral NFs lines were derived from oral mucosa and cultured successfully. All cultured cells were positive for vimentin; however, all cells were negative for cytokeratin (Fig. 2A). The expression of α-SMA is a defining feature of MFs and CAFs (18). Immunostaining for intracellular cytoskeletal proteins demonstrated an increased proportion of α-SMA and FAP antibody expression in OLP-MFs. However, neither were expressed by NFs. Transmission electron microscopy demonstrated typical morphological structures in OLP-MFs cells, including large spindle shapes, peripheral filaments and focal density (red arrow), which were absent in NFs (Fig. 2B). Moreover, scanning electron microscopy demonstrated that OLP-MFs exhibited fusiform or polygonal shapes with slab-shaped pseudopods (white arrow) and a pile of elastic fibers (red arrow) resembling smooth muscles that are formed in the cytoplasm and usually arranged parallel to the cell axis, while NFs present long and thin spindle shape. (C) Cell Counting Kit-8 assays demonstrated that OLP-MFs had a significantly higher hyperplasia ability compared with NFs. (D) Wound healing assays revealed that increased numbers of OLP-MFs migrated compared with NFs. (E) The migration rate of OLP-MFs was higher compared with NFs. *P<0.05, **P<0.01, ***P<0.001 vs. NFs. OLP, oral lichen planus; MFs, myofibroblasts; α-SMA, α-smooth muscle actin; FAP, fibroblast activation protein; NFs, normal fibroblasts; OD, optical density; ns, not significant; TEM, transmission electron microscopy; SEM, scanning electron microscopy.

### Table III. Comparison of ICAM-1, VCAM-1 and VEGF positive cells between groups.

| Group   | ICAM-1 (%) | VCAM-1 (%) | VEGF (%)  |
|---------|------------|------------|-----------|
| Normal  | 1.99±3.67% | 2.33±4.28% | 3.20±5.40%|
| OLP     | 36.96±15.59% | 29.32±6.06% | 41.56±15.99% |
| t-value | -10.74     | -15.09     | -10.99    |
| P-value | P<0.001    | P<0.001    | P<0.001   |

P<0.001 normal group vs. OLP group. ICAM-1, intercellular adhesion molecular 1; VCAM-1, vascular cell adhesion molecule 1; VEGF, vascular endothelial growth factor; OLP, oral lichen planus.

### Table IV. Comparison of MVD between groups.

| Group            | MVD (mean ± SD) | t-value | P-value |
|------------------|-----------------|---------|---------|
| Normal tissues   | 23.05±6.58      | -7.171a | P<0.001a |
| OLP tissues      | 58.82±11.44     | -4.982b | P<0.001b |
| NEOLP group      | 87.89±15.45     |         |         |

P<0.05 vs. OLP tissues group; *P<0.01 vs. EOLP group. MVD, microvessel density; OLP, oral lichen planus; EOLP, erosive OLP; NEOLP, non-erosive OLP.
XU et al: IL-6 PROMOTES ANGIOGENESIS IN OLP

are formed in the cytoplasm and usually arranged in parallel to the cell axis. The biological characteristics of OLP-MFs were evaluated by CCK-8 assays, which revealed that the OLP-MFs exhibited a significantly higher hyperplasia ability compared with NFs at 48 and 72 h post-culture (Fig. 2C). Furthermore, wound healing assays were conducted to investigate the migratory ability of OLP-MFs. The scratch width of OLP-MFs and NFs at 24 and 48 h was markedly narrower compared with 0 h (Fig. 2D). Additionally, at both time points, increased numbers of OLP-MFs migrated compared with NFs. Statistically, the rate of migration of OLP-MFs was 80%, whereas that of NFs was 60% (Fig. 2E). These results indicated that certain specific ultrastructures in OLP-MFs changed and that OLP-MFs exhibited higher proliferative and migratory abilities compared with NFs.

Increased IL-6 is released from MFs compared with NFs in vitro. Dual immunofluorescence staining of normal tissues demonstrated that IL-6 was not expressed in the epithelium or stroma, whereas α-SMA-positive vascular endothelial cells (yellow arrows) formed as vessels. Magnification, ×200. (B) The same field of view revealed that all OLP-MFs were positive for IL-6 and α-SMA, whereas NFs were weakly stained for IL-6 and slightly positive for α-SMA. Magnification, ×400. In OLP-MFs, the relative mRNA expression of (C) IL-6 and (D) α-SMA was higher compared with NFs. (E) The results of Simple Western analysis demonstrated that the expression of α-SMA (48 kDa) and IL-6 (58 kDa) in OLP-MFs was detected. NFs exhibited weak IL-6 expression and rare expression of α-SMA protein. IL-6, interleukin 6; OLP, oral lichen planus; α-SMA, α-smooth muscle actin; MFs, myofibroblasts; NFs, normal fibroblasts; E, epithelium; S, stroma; bm, basement membrane.

Moreover, gene expression and secretion of IL-6 in NFs and OLP-MFs were evaluated (n=3). RT-qPCR reported that the relative mRNA expression of IL-6 in OLP-MFs was 5-6 times higher compared with NFs (Fig. 3C), whereas that of α-SMA in OLP-MFs was 30-40-fold higher as compared with NFs (Fig. 3D). Simple Western analysis demonstrated 48-kDa and 58-kDa bands in OLP-MFs, which were consistent with the size of α-SMA and IL-6, respectively (Fig. 3E). In NFs, weak IL-6 bands were expressed, whereas α-SMA bands were barely detected. As α-SMA is an indicator of MFs, these results revealed that OLP-MFs were a crucial source of IL-6.

Inflammation promotes IL-6 expression by stromal fibroblasts. ELISA results revealed that the expression of IL-6 in NFs peaked on day 3 or 4 in the four subgroups, NFs, NFs-LPS stimulation, OLP/MFs and OLP/MFs-LPS, and then declined (Fig. 4A). LPS is known to promote the inflammation and secretion of inflammatory factors (5). The secretion of IL-6 by NFs was increased following LPS stimulation, which was similar to the expression level of OLP-MFs (Fig. 4A). These data indicated that inflammation increased the secretion of IL-6 in fibroblasts. Irrespective of the stimulation of OLP-MFs by LPS, the overall expression level of IL-6 was higher compared with the NFs groups. RT-qPCR results demonstrated that the expression of IL-6 mRNA in OLP-MFs was significantly higher compared with NFs at the four time points (0, 12, 24 and 48 h; Fig. 4B) and protein expression levels revealed similar results (Fig. 4C). Therefore, RT-qPCR and Simple Western analysis results reported that the expression of IL-6 in OLP-MFs decreased with time and that NFs exhibited non-significant,
Figure 4. Inflammation promotes IL-6 expression. (A) ELISA demonstrated that the overall expression levels of IL-6 in the OLP-MF groups were similar and significantly higher compared with the NF groups, and the secretion of IL-6 by NFs was significantly increased following LPS stimulation. (B) Reverse transcription-quantitative PCR and (C) Simple Western analysis demonstrated that the expression of IL-6 mRNA and protein in OLP-MFs was significantly higher compared with NFs at the four time points. Furthermore, the expression of IL-6 in OLP-MFs decreased with time. *P<0.05, **P<0.01 vs. NFs. IL-6, interleukin 6; OLP, oral lichen planus; MFs, myofibroblasts; NFs, normal fibroblasts; LPS, lipopolysaccharide.

Figure 5. IL-6 promotes VCAM-1, ICAM-1 and VEGF expression. (A) Reverse transcription-quantitative PCR and (B) ELISA demonstrated that IL-6 significantly promoted the expression of VCAM-1, ICAM-1, and VEGF in OLP-MFs and NFs. MRA significantly decreased the secretion of vascular-related growth factors in the OLP-MFs group compared with the control group. The expression of angiogenesis-associated cytokines in the OLP-MFs group were significantly higher compared with the NFs group. Control group, cells without treatment; IL-6 group, cells were treated with IL-6/sIL-6R; IL-6+MRA group, cells were treated with IL-6/sIL-6R and MRA. *P<0.05, **P<0.01 and ***P<0.001. IL-6, interleukin 6; VCAM-1, vascular cell adhesion molecule 1; ICAM-1, intercellular adhesion molecule 1; VEGF, vascular endothelial growth factor; OLP, oral lichen planus; MFs, myofibroblasts; NFs, normal fibroblasts; MRA, tocilizumab; ns, not significant.
weak IL-6 expression. Thus, IL-6 was primarily derived from OLP-MFs and inflammatory reactions, and was gradually secreted into the culture supernatants.

IL-6 promotes VCAM-1, ICAM-1 and VEGF expression by fibroblasts, particularly by OLP-MFs. To further clarify whether IL-6 promoted angiogenesis, NFs and OLP-MFs were grouped for the treatment with IL-6/sIL-6R and MRA. The relative mRNA expression of VCAM-1, ICAM-1 and VEGF was significantly increased in OLP-MFs and NFs stimulated by IL-6/sIL-6R, compared with the control group. However, the expression of VCAM-1, ICAM-1 and VEGF was decreased in OLP-MFs and NFs following treatment with 10 µg/ml MRA, compared with the IL-6/sIL-6R treatment (Fig. 5A). In terms of changes in overall expression levels, the relative mRNA expression of angiogenesis-associated cytokines in the NFs group treated with IL-6/sIL-6R and MRA was similar to the OLP-MFs group; however, the expression of VCAM-1, ICAM-1 and VEGF in the OLP-MFs group was still significantly higher than the NFs group, when cells were treated with IL-6/sIL-6R (Fig. 5A). ELISA results revealed that IL-6 significantly promoted the secretion of VCAM-1, ICAM-1 and VEGF in OLP-MFs and NFs compared with the control group (Fig. 5B). MRA significantly decreased the secretion of vascular-related growth factors by OLP-MFs compared with the control group (Fig. 5B).

IL-6 signaling by OLP-MFs promotes the angiogenic potential of HUVECs. Cell migration assays demonstrated that IL-6 promoted the migratory ability of OLP-MFs and NFs (Fig. 6A). Notably, OLP-MFs exhibited stronger migratory ability compared with NFs. Moreover, MRA weakly suppressed the migratory ability of OLP-MFs and NFs compared with the control group. Statistically, the numbers of migrated OLP-MF and NF cells were significantly increased in the IL-6/sIL-6R-treated group compared with the control group (P<0.01) (Fig. 6B). However, there was no significant difference in numbers of migrated cells following MRA treatment compared with the IL-6/sIL-6R-treated group in both cell groups. Numbers of migrated OLP-MFs and NFs in the MRA-treated group did not differ significantly with the control group (Fig. 6C).

Matrigel capillary germination assays were used to analyze the effects of IL-6/sIL-6 and MRA on the angiogenic potential of HUVECs in vitro. The results demonstrated that HUVECs formed capillary buds at 3 h (Fig. 6D). Furthermore, numerous HUVECs formed into blood vessels post-IL-6/sIL-6R treatment and markedly blood vessel density was measured. The
formation of blood vessels was highest at 6 h. Moreover, the number and density of blood vessels formed by HUVECs were markedly reduced following treatment with MRA. Numbers of capillary branch points (Fig. 6E) and blood vessel branches (Fig. 6F), and tube lengths (Fig. 6G) formed by IL-6/sIL-6R-treated HUVECs were significantly higher compared with the control group. Following the addition of MRA, the three indexes were significantly lower compared with the IL-6/sIL-6R treatment group.

Discussion

OLP has been regarded as a non-specific inflammatory condition due to its pathological and micrographic features, including hand-like infiltration of superficial lymphocytes in the lamina propria and infiltration of inflammatory cytokines (19). Angiogenesis is of considerable concern during the development of chronic inflammatory disorders (20-23). Previous IHC-based studies reported a strong involvement of the angiogenic phenomenon in the malignant transformation of precancerous lesions, including OLP (24-26). VEGF, ICAM-1 and VCAM-1 have been regarded as critical angiogenic factors that directly mediate OLP angiogenesis (27,28). Additionally, the current IHC data demonstrated the high expression of angiogenic factors in OLP tissues according to the percentage of stained cells. Additionally, MVD in OLP tissue increased with the deterioration of the lesion. Previous results, together with those from the present study, indicated that increased angiogenesis may serve a vital role in the malignant transformation of OLP (29,30). However, the mechanism underlying this phenomenon remains unclear. The dynamic interplay between multiple cell types, including MFs, immune cells, endothelial cells and adipocytes, in the microenvironment of the lesion has gained interest as a promising target for the treatment of inflammatory diseases (31). Previous studies have demonstrated that MFs and NFs produce significant amounts of IL-6 in the presence of cancer cells (32,33). Furthermore, IL-6 stimulation significantly increased the expression of VEGF in stroma fibroblasts. Therefore, it was hypothesized that IL-6 released by MFs is critical for OLP angiogenesis.

In order to verify this hypothesis, eight primary OLP-MF lines were isolated and cultured. OLP-MFs acquired characteristics and biological behavior of MFs, including the expression of α-SMA and FAP markers (34). To identify these stromal cells dual immunofluorescence staining was used and combined with observation of the morphology of the isolated cells. Notably, OLP-MFs exhibited a significantly high expression of IL-6 at the mRNA and protein levels as compared with NFs. Additionally, fibroblasts produced IL-6 under inflammatory conditions and markedly upregulated the level of IL-6 following treatment with LPS. To the best of our knowledge, this is the first report of the expression of IL-6 in OLP stroma fibroblasts. Furthermore, the present study demonstrated that IL-6 facilitated OLP angiogenesis via the induction of angiogenesis-related proteins in OLP-MFs. The secreted angiogenic factors from OLP-MFs subsequently induced angiogenesis. The current results indicated that IL-6-stimulated OLP-MFs significantly facilitated the migration of HUVECs and tube length formation. Based on this model, it was concluded that IL-6-induced inflammation in OLP-MFs induced the surrounding activated fibroblasts to express VEGF, ICAM-1 and VCAM-1. Consequently, angiogenesis was induced. In a previous study, anti-human IL-6 receptor antibodies were used to remove the blockade of the IL-6 receptor (35). MRA successfully inhibited cell migration and tube formation. IL-6 was observed to be one of the primary inducers of OLP angiogenesis; however, there are still other associated mechanisms that require further research. Therefore, OLP-MFs serve a major role in mediating IL-6-induced OLP angiogenesis. Thus, we hypothesized that the modulation between OLP-MFs and angiogenesis may have a primary role in the pathological process underlying OLP.

Taken together, these data indicated that increased angiogenesis was a common event and served a critical role in OLP pathogenesis. OLP-MFs and NFs produced significant amounts of IL-6 in the presence of inflammatory factors. Therefore, the anti-IL-6 receptor antibodies and the target OLP-MFs may serve as novel therapeutic agents capable of inhibiting the malignant transformation of OLP.

Acknowledgements

Not applicable.

Funding

The present study was funded by the National Natural Science Foundation of China (grant no. 81500850) and the Nonprofit Industry Research Specific Fund of National Health and Family Planning Commission of China (grant no. 201502018).

Availability of data and materials

The datasets used and/or analyzed during the present study are available from the corresponding author on reasonable request.

Authors' contributions

XHX and YL contributed to the conception and design of the present study, performed the data acquisition and interpretation, and drafted and critically revised the manuscript. LF contributed to the conception, data acquisition and analysis, and drafted and critically revised the manuscript. YSY contributed to the data acquisition and interpretation, and drafted and critically revised the manuscript. SGL, WG and HXZ contributed to the conception and design of the present study, performed the data acquisition and interpretation, and drafted and critically revised the manuscript. ZQL and LZ contributed to the data acquisition and analysis, and critically revised the manuscript. WXM contributed to the data acquisition and interpretation, and drafted and critically revised the manuscript. All authors read and approved the final manuscript.

Ethics approval and consent to participate

The present study was reviewed by the Institutional Ethics Committee of the Stomatological Hospital, Southern Medical University, Guangzhou, China [approval no. (2019)26]. Each patient signed the informed consent form.
Patient consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

References

1. Rode M and Kogoi-Rode M: Malignant potential of the reticular form of oral lichen planus over a 25-year observation period in 55 patients from Slovenia. J Oral Sci 44: 109-111, 2002.

2. Brown RS, Bottomley WK, Puente E and Lavigne GJ: A retrospective evaluation of 193 patients with oral lichen planus. J Oral Pathol Med 22: 69-72, 1993.

3. Lanfranchi-Tizeira HE, Aguas SC and Sano SM: Malignant transformation of atypical oral lichen planus: A review of 32 cases. Med Oral 8: 2-9, 2003 (In English, Spanish).

4. Malekzadeh H, Robati M, Yousefimanesh H, Ghaffourian Boroujerdinia M and Nadirpour R: Salivary interferon gamma and interleukin-4 levels in patients suffering from oral lichen planus. Cell J 17: 554-558, 2015.

5. Al-Hassiny A, Friedlander LT, Parachuru VPB, Seo B, Hussaini HM and Rich AM: Uptregulation of angiogenesis in oral lichen planus. J Oral Pathol Med 47: 173-178, 2018.

6. Mahmoud MM and Afifi MM: Anti-angiogenic therapy (bevacizumab) in the management of oral lichen planus. Eur J Oral Sci 124: 119-126, 2016.

7. Meng W, Wu Y, He X, Liu C, Gao Q, Ge L, Wu L, Liu Y, Guo Y, Li X, et al: A systems biology approach identifies effective tumour-stroma interaction. Br J Cancer 110: 469-478, 2014.

8. She G, Ren YJ, Wang Y, Hou MC, Wang HF, Gou W, Lai BC, Lei T, Du W, Deng XL, Ke C, et al: Kc3.1 channels promote cardiac fibrosis through mediating inflammation and differentiation of monocytes into myofibroblasts in angiotensin II-treated rats. J Am Heart Assoc 8: e010418, 2019.

9. Cadamuro M, Brivio S, Mertens J, Vismara M, Moncek A, Milani C, Fingas C, Cristina Malerba M, Nardo G, Dolf'Olmo L, Platelet-derived growth factor-D1 enzymes liver myofibroblasts to promote tumor lymphangiogenesis in cholangiocarcinoma. J Hepatol 70: 700-709, 2019.

10. Lemoine S, Cadoret A, Rautou PE, El Mourabit H, Ratzin V, Hendrayani SF, Al-Harbi B, Al-Ansari MM, Silva G, Al-Ansari  MM and Aboussekhra A: The inflammatory/cancer-related receptor antibody suppressed angiogenesis and inhibited pro-tumorigenic functions of breast stromal fibroblasts. Oncotarget 9: 34681-34690, 2018.

11. Wang L, Yang Y, Xiong X, Yu T, Wang X, Meng W, Wang H, Luo G and Ge L: Oral lichen-planus-associated fibroblasts acquire myofibroblast characteristics and secrete pro-inflammatory cytokines in response to Porphyromonas gingivalis lipopolysaccharide stimulation. BMC Oral Health 18: 197, 2019.

12. Karakasheva TA, Lin EW, Tang Q, Qiao E, Waldron TJ, Soni M, Klein-Szanto AJL, Sahu V, Basu D, Ohashi S, et al: IL-6 mediates cross-talk between tumor cells and activated fibroblasts in the tumor microenvironment. Cancer Res 78: 4957-4970, 2018.

13. Mirkeshevzvar M, Ganjibakhsh M, Aminishakib P, Farzaneh P, Mahdavi N, Vakhshtieh F, Karimi A, Gohari NS, Kamali F, Shokrzadifard MJ, et al: Interleukin-6-secreted by oral cancer-associated fibroblast accelerated VEGF expression in tumor and stroma cells. Cell Mol Biol (Noisy-le-grand) 63: 131-136, 2017.

14. Weidner N, Semple JP, Welch WR and Folkman J: Tumor angiogenesis and metastasis-correlation in invasive breast carcinoma. N Engl J Med 324: 1-8, 1991.

15. Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods 25: 402-408, 2001.

16. Tabeobordbar M, Zhu K, Cheng JKW, Chew WL, Widrick JJ, Yan WX, Maenner C, Wu YY, Xiao R, Ran FA, et al: In vivo gene editing in dystrophic mouse muscle and muscle stem cells. Science 351: 407-411, 2016.